MYTHF yields 2.09% · JNJ yields 2.13%● Live data
📍 MYTHF pulled ahead of the other in Year 1
Combined, MYTHF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MYTHF + JNJ for your $10,000?
Mytilineos S.A. operates in metallurgy, sustainable engineering solution, renewables and storage development, and power and gas sectors in Greece, the European Union, and internationally. Its principal business areas include the production of electricity and natural gas; operation of industrial and renewable energy plants; trading of gas; production of alumina and aluminum, as well as bauxite and recycled aluminum; and production, processing, and trading of metals, which include aluminum alloys and derivative products. The company also engages in the development and contract of solar and energy storage projects; contract of specialized large-scale integrated turn-key projects; construction of infrastructure projects; and provision of photovoltaic construction, as well as environmental solutions for water, liquid, and solid waste. In addition, it provides energy solutions; and a range of project management, engineering, procurement, construction, and plant commissioning services. The company was formerly known as Mytilineos Holdings S.A. and changed its name to Mytilineos S.A. in July 2019. Mytilineos S.A. was founded in 1908 and is headquartered in Athens, Greece.
Full MYTHF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.